Amid Torrent Of Next-Gen Anticoagulant Data, Trial Design Differences Complicate Comparisons Between Potential Competitors
This article was originally published in Pharmaceutical Approvals Monthly
As pivotal data on the new generation of anticoagulants continue to become public, differences in trial design and population are confusing attempts to predict competitive positioning for the new agents.
You may also be interested in...
FDA has agreed to review the anticoagulant based on the results of the AVERROES trial, offering a potentially faster route to market.
Pradaxa, the Boehringer Ingelheim drug that FDA approved on Oct. 19, is the first of several oral anti-coagulants that could come on the U.S. market near-term and shake up existing standards of care.
The pivotal issue remaining for FDA's review of Boehringer Ingelheim's Pradaxa (dabigatran) is whether it will clear both the 110 mg and 150 mg doses and how it can craft labeling to guide appropriate use toward the higher dose, which seems likely to gain a superiority claim over warfarin.